Investment analysts at Jefferies Financial Group assumed coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) in a research note issued to investors on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $35.00 price target on the stock.
Separately, Stifel Nicolaus assumed coverage on Rapport Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 price target for the company.
Get Our Latest Stock Report on RAPP
Rapport Therapeutics Stock Performance
Read More
- Five stocks we like better than Rapport Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- Snowflake Stock Rebounds, Flies Higher on AI Spending
- Why Invest in 5G? How to Invest in 5G Stocks
- Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
- Investing in the High PE Growth Stocks
- Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
